人福医药：关于HW231019片进入Ⅱ期临床试验研究的公告

Core Viewpoint - The announcement indicates that the company’s subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has registered the Phase II clinical trial information for HW231019 tablets with the National Medical Products Administration [1] Group 1 - The company holds an 80% stake in Yichang Renfu Pharmaceutical Co., Ltd. [1] - The registration of the clinical trial is a significant step in the drug development process [1]